The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.

Company Guidance

During the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call, the company provided guidance on its development activities and financial performance. Viking Therapeutics reported a net loss of $90.8 million for the third quarter of 2025, an increase from the $24.9 million loss reported in the same period in 2024, primarily due to a rise in research and development expenses, which reached $90 million. The company highlighted the progress of its VK2735 program, including the successful achievement of primary and secondary endpoints in the Phase II VENTURE-Oral Dosing Trial, with statistically significant reductions in body weight observed. Viking also announced the initiation of a clinical study to evaluate maintenance dosing strategies for VK2735, which includes monthly subcutaneous, daily oral, and weekly oral dosing options. The company's cash reserves stood at $715 million as of September 30, 2025, providing sufficient financial resources to complete planned Phase III trials and support further program development.

Positive Phase II Results for VK2735

The Phase II VENTURE-Oral Dosing Trial successfully achieved its primary and secondary endpoints with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo. Up to 97% of subjects achieved at least 5% weight loss.

Initiation of Phase III VANQUISH Registration Program

Viking initiated the Phase III VANQUISH Registration program, including trials in patients with obesity and patients with obesity and type 2 diabetes. Enrollment for these trials is proceeding well and is ahead of schedule.

Strong Financial Position

Viking holds cash, cash equivalents, and short-term investments of $715 million as of the end of the third quarter, which allows the company to complete its planned Phase III obesity trials for VK2735.

Viking Therapeutics (DE:1VT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:1VT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 11, 2026	2025 (Q4)	-0.77 / -	-0.273	―	―	―
Oct 22, 2025	2025 (Q3)	-0.61 / -0.69	-0.188	-268.18% (-0.50)	―
Jul 24, 2025	2025 (Q2)	-0.38 / -0.50	-0.171	-190.00% (-0.32)	―
Apr 23, 2025	2025 (Q1)	-0.28 / -0.35	-0.222	-57.69% (-0.13)	―
Feb 05, 2025	2024 (Q4)	-0.24 / -0.27	-0.213	-28.00% (-0.06)	―
Oct 23, 2024	2024 (Q3)	-0.21 / -0.19	-0.196	4.35% (<+0.01)	―
Jul 24, 2024	2024 (Q2)	-0.22 / -0.17	-0.162	-5.26% (>-0.01)	―
Apr 24, 2024	2024 (Q1)	-0.24 / -0.22	-0.213	-4.00% (>-0.01)	―
Feb 07, 2024	2023 (Q4)	-0.22 / -0.21	-0.222	3.85% (<+0.01)	―
Oct 25, 2023	2023 (Q3)	-0.19 / -0.20	-0.179	-9.52% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:1VT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 22, 2025	€27.89	€29.99	+7.51%
Jul 24, 2025	€29.12	€29.10	-0.07%
Apr 23, 2025	€21.82	€22.01	+0.85%
Feb 05, 2025	€32.20	€29.40	-8.70%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Viking Therapeutics (DE:1VT) report earnings?

Viking Therapeutics (DE:1VT) is schdueled to report earning on Feb 11, 2026, After Close (Confirmed).

What is Viking Therapeutics (DE:1VT) earnings time?

Viking Therapeutics (DE:1VT) earnings time is at Feb 11, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Viking Therapeutics stock?

The P/E ratio of Viking Therapeutics is N/A.

What is DE:1VT EPS forecast?

DE:1VT EPS forecast for the fiscal quarter 2025 (Q4) is -0.77.